AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33629219 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I
Number of subjects: 160
Study 33629219 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160
Study 35486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormonal contraceptive pill (OC) during high estradiol (HE) phase
Number of subjects: 21
Study 35486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormonal contraceptive pill (OC) during low estradiol (LE) phase
Number of subjects: 21
Study 35486478 — intervention group
Group type: COMPARATOR
Intervention: Natural menstrual cycles (NC) during high estradiol (HE) phase
Number of subjects: 21
Study 35486478 — intervention group
Group type: COMPARATOR
Intervention: Natural menstrual cycles (NC) during low estradiol (LE) phase
Number of subjects: 21
Study 32931763 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy (3 sessions, 1 week apart, using Robert Maigne's technique)
Number of subjects: 44
Study 32931763 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (control group)
Number of subjects: 44
Study 32792454 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) for 30 minutes/day, 5 days/week, for 6-9 weeks starting within 40 days after SCI.
Number of subjects: 114
Study 32792454 — intervention group
Group type: COMPARATOR
Intervention: Sham TTNS (control group).
Number of subjects: 114
Study 32792454 — intervention group
Group type: EXPERIMENTAL
Intervention: TTNS (intervention).
Number of subjects: 114
Study 32441852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast enteral advancement (30 mL/kg/d for 1000-1499 g; 40 mL/kg/d for 1500-1999 g)
Number of subjects: 0
Study 32441852 — intervention group
Group type: COMPARATOR
Intervention: Traditional enteral advancement (20 mL/kg/d)
Number of subjects: 0
Study 32308126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischial ramus containment socket
Number of subjects: 0
Study 32308126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic socket
Number of subjects: 0
Study 32308126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-ischial socket
Number of subjects: 0
Study 36463178 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/NIV starting at P/F ≤ 200 (Group A)
Number of subjects: 146
Study 36463178 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/NIV starting at P/F ≤ 150 (Group B)
Number of subjects: 146
Study 36463178 — intervention group
Group type: COMPARATOR
Intervention: CPAP/NIV starting at P/F ≤ 100 (Group C)
Number of subjects: 146
Study 36463178 — intervention group
Group type: COMPARATOR
Intervention: CPAP/NIV starting at P/F between 151 and 200
Number of subjects: 146
Study 33254171 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with confirmed SARS-CoV-2 infection
Number of subjects: 3
Study 36254455 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief social contact‐based videos (traditional or selfie styles)
Number of subjects: 1532
Study 36254455 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional videos
Number of subjects: 1532
Study 36254455 — intervention group
Group type: EXPERIMENTAL
Intervention: Selfie videos
Number of subjects: 1532
Study 36254455 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1532
Study 34498944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise with low-pressure blood flow restriction (BFR40)
Number of subjects: 0
Study 34498944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise with high-pressure blood flow restriction (BFR80)
Number of subjects: 0
Study 34498944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (HI-AE)
Number of subjects: 0
Study 34498944 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity aerobic exercise (LI-AE)
Number of subjects: 0
Study 36357840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous IAA
Number of subjects: 0
Study 36357840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous ABA
Number of subjects: 0
Study 36357840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous ABA or IAA
Number of subjects: 0
Study 36241582 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training intervention with task interruptions (TI)
Number of subjects: 21
Study 36241582 — intervention group
Group type: COMPARATOR
Intervention: Control training session (without interruption)
Number of subjects: 21
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrown with an empty pulp chamber (EC)
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay preparation with EverX Posterior (OE)
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay preparation with G‐aenial Universal Flo (OG)
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD inlay preparation with EverX Posterior (IE)
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD inlay preparation with G‐aenial Universal Flo (IG)
Number of subjects: 180
Study 33219727 — intervention group
Group type: COMPARATOR
Intervention: Control group without access cavity preparation (C)
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlays with EverX Posterior
Number of subjects: 180
Study 33219727 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlays with G‐aenial Universal Flo
Number of subjects: 180
Study 32280282 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 mcg/DRSP 3 mg in an extended regimen (EE/DRSPes group)
Number of subjects: 348
Study 32280282 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 mcg/DRSP 3 mg in an extended regimen with 4-day hormone-free interval
Number of subjects: 348
Study 35610018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 12
Study 35610018 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous non-auricular vagus nerve stimulation (tnVNS)
Number of subjects: 12
Study 34708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running (DR trial, -15% slope) at 60% O2max for 30 min
Number of subjects: 9
Study 34708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Level running (trial) at 60% O2max for 30 min
Number of subjects: 9
Study 34708716 — intervention group
Group type: COMPARATOR
Intervention: Rest (CON trial)
Number of subjects: 9
Study 32195370 — intervention group
Group type: EXPERIMENTAL
Intervention: CureApp Smoking Cessation (CASC) system including a smartphone app, web-based patient management software, and mobile CO checker
Number of subjects: 584
Study 32195370 — intervention group
Group type: COMPARATOR
Intervention: Control app without a mobile CO checker
Number of subjects: 584
Study 33719786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications (one-drug, two-drug, three-drug, four-drug regimens)
Number of subjects: 95
Study 33719786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications
Number of subjects: 95
Study 32467335 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m²
Number of subjects: 1618
Study 35562406 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate-cytarabine (arm A)
Number of subjects: 219
Study 35562406 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate-cytarabine-rituximab (arm B)
Number of subjects: 219
Study 35562406 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C)
Number of subjects: 219
Study 35562406 — intervention group
Group type: COMPARATOR
Intervention: whole-brain irradiation (WBRT)
Number of subjects: 219
Study 35562406 — intervention group
Group type: COMPARATOR
Intervention: carmustine-thiotepa-conditioned autologous transplantation (ASCT)
Number of subjects: 219
Study 34289708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion evolution measured by noncontrast CT at 24 hours and 1 week after stroke onset
Number of subjects: 226
Study 34289708 — intervention group
Group type: COMPARATOR
Intervention: Successful recanalization (defined as modified Arterial Occlusion Lesion score of 3 points)
Number of subjects: 226
Study 32232637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2, single intravenous infusion)
Number of subjects: 30
Study 32232637 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (control group)
Number of subjects: 30
Study 36216005 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 0
Study 36216005 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 35248276 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft and prolonged massage with roghan‐i‐suranjan
Number of subjects: 40
Study 35248276 — intervention group
Group type: COMPARATOR
Intervention: Short wave diathermy
Number of subjects: 40
Study 34477026 — intervention group
Group type: EXPERIMENTAL
Intervention: 29°C
Number of subjects: 144
Study 34477026 — intervention group
Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 144
Study 34477026 — intervention group
Group type: EXPERIMENTAL
Intervention: 35°C
Number of subjects: 144
Study 34477026 — intervention group
Group type: COMPARATOR
Intervention: 26°C (control)
Number of subjects: 144
Study 34053177 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 3636
Study 34053177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3636
Study 32705392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.13) during shoulder press in failure sessions
Number of subjects: 20
Study 32705392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.13) during shoulder press in non-failure sessions
Number of subjects: 20
Study 32705392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.13) during bench press in non-failure sessions
Number of subjects: 20
Study 32705392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.13) during non-failure sessions
Number of subjects: 20
Study 32705392 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FiO2 = 0.21)
Number of subjects: 20
Study 34399358 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training program of supervised, task‐specific training
Number of subjects: 20
Study 34399358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured training)
Number of subjects: 20
Study 34399358 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training program
Number of subjects: 20
Study 33682431 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial adjudication and claims
Number of subjects: 1336
Study 33682431 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial adjudication only
Number of subjects: 1336
Study 33682431 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims only
Number of subjects: 1336
Study 33682431 — intervention group
Group type: COMPARATOR
Intervention: No ischemic events
Number of subjects: 1336
Study 33682431 — intervention group
Group type: COMPARATOR
Intervention: No bleeding events
Number of subjects: 1336
Study 33682431 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims only (no trial-adjudicated events)
Number of subjects: 1336
Study 32375634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroplast transcriptome analysis under drought conditions
Number of subjects: 1
Study 32375634 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcription (RT)-qPCR of 9 cpDEGs
Number of subjects: 1
Study 32375634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis using chloroplast genome sequences of 23 Populus plants
Number of subjects: 1
Study 32375634 — intervention group
Group type: EXPERIMENTAL
Intervention: mVISTA analysis of chloroplast genome
Number of subjects: 1
Study 35481707 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon CNP (75-150 μg CNP/kg)
Number of subjects: 45
Study 35481707 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Number of subjects: 45
Study 35481707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34293624 — intervention group
Group type: EXPERIMENTAL
Intervention: Guo Qing Yi Tang (GQYT) combined with Western medicine cluster therapy
Number of subjects: 138
Study 34293624 — intervention group
Group type: COMPARATOR
Intervention: Cluster therapy alone
Number of subjects: 138
Study 35072307 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 54
Study 35072307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 35474455 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 86
Study 35474455 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (END)
Number of subjects: 86
Study 34688229 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath™ MAC videolaryngoscope
Number of subjects: 28
Study 34688229 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 28
Study 34688229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 28
Study 34954864 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX chemotherapy
Number of subjects: 74
Study 34954864 — intervention group
Group type: COMPARATOR
Intervention: Immune profiling of primary CRC
Number of subjects: 74
Study 32778907 — intervention group
Group type: EXPERIMENTAL
Intervention: Active heel-slide exercise (AHSE) + standard physiotherapy (PT)
Number of subjects: 0
Study 32778907 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion (CPM) + standard physiotherapy (PT)
Number of subjects: 0
Study 35190477 — intervention group
Group type: COMPARATOR
Intervention: Masitinib 4.5 mg/kg/d
Number of subjects: 611
Study 35190477 — intervention group
Group type: COMPARATOR
Intervention: Masitinib 6.0 mg/kg/d
Number of subjects: 611
Study 35190477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 32481374 — intervention group
Group type: EXPERIMENTAL
Intervention: Warrior emergency simulator
Number of subjects: 20
Study 33334174 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ketorolac and Marcaine infiltration
Number of subjects: 80
Study 33334174 — intervention group
Group type: COMPARATOR
Intervention: Popliteal nerve block
Number of subjects: 80
Study 33057344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid seeding approach with n ≤ 256
Number of subjects: 2001
Study 33057344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid seeding approach
Number of subjects: 2001
Study 34843870 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 μg of d3‐vitamin D3
Number of subjects: 0
Study 34894316 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Postoperative Treatment (SPT)
Number of subjects: 154
Study 34894316 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Approach (SA)
Number of subjects: 154
Study 32985539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (1,000 mg)
Number of subjects: 57
Study 32985539 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 57
Study 35398843 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Training (AT) program for 8 weeks including sound discrimination and cognitive exercises
Number of subjects: 33
Study 35398843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AT)
Number of subjects: 33
Study 32717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion workshop with Facebook group discussion (50-minute workshop)
Number of subjects: 76
Study 32717627 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 76
Study 36608978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Body Dysmorphic Disorder (CT‐BDD)
Number of subjects: 40
Study 36608978 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 40
Study 34301736 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT diet
Number of subjects: 225
Study 34301736 — intervention group
Group type: COMPARATOR
Intervention: MED diet
Number of subjects: 225
Study 33142493 — intervention group
Group type: COMPARATOR
Intervention: Dietary manganese supplementation (20, 40, 80, 120, or 160 mg/kg of Mn as MnSO4·H2O)
Number of subjects: 504
Study 33142493 — intervention group
Group type: COMPARATOR
Intervention: Dietary manganese supplementation
Number of subjects: 504
Study 35242590 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone-based intervention
Number of subjects: 166
Study 35242590 — intervention group
Group type: COMPARATOR
Intervention: goal-setting control group
Number of subjects: 166
Study 33875484 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec titration A (prebreakfast self-measured blood glucose target 80-130 mg/dL; adjustment ±21 units/week; n = 51)
Number of subjects: 205
Study 33875484 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec titration B (80-130 mg/dL; ±28 units/week; n = 51)
Number of subjects: 205
Study 33875484 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec titration C (70-108 mg/dL; ±28 units/week; n = 52)
Number of subjects: 205
Study 33875484 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (IGlar U100) (80-130 mg/dL; ±4 units/day; n = 51)
Number of subjects: 205
Study 33875484 — intervention group
Group type: COMPARATOR
Intervention: Insulin icodec titration B vs IGlar U100
Number of subjects: 205
Study 33875484 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, IGlar U100)
Number of subjects: 205
Study 35749631 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (specific regimens not detailed)
Number of subjects: 1373
Study 35749631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin treatment
Number of subjects: 1373
Study 35749631 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese/overweight patients
Number of subjects: 1373
Study 35749631 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with normal baseline weight
Number of subjects: 1373
Study 35749631 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 1373
Study 35749631 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 1373
Study 34081614 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminizing hormonal treatment (GAHT) including natural estrogen (estradiol) and testosterone-blocking treatments such as cyproterone acetate, GnRH agonist, or spironolactone.
Number of subjects: 0
Study 34081614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate as anti-androgen treatment.
Number of subjects: 0
Study 34081614 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone as part of GAHT.
Number of subjects: 0
Study 34081614 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy after various durations of GAHT.
Number of subjects: 0
Study 36396162 — intervention group
Group type: EXPERIMENTAL
Intervention: Face‐to‐face presentations, printed information, and additional components
Number of subjects: 95
Study 36396162 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders and multicomponent strategies including provider-level interventions
Number of subjects: 95
Study 36396162 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions that did not lead to improvement in HPV vaccination intention or uptake
Number of subjects: 95
Study 32873147 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 173
Study 32873147 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 173
Study 36056362 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy (4 sessions of 90 minutes each, divided over two half-days)
Number of subjects: 14
Study 36056362 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 14
Study 36056362 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study 33300371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 100
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl benzoate (25% or 10%) for daily use over three consecutive days
Number of subjects: 224
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 μg/kg body weight) twice, 1 week apart
Number of subjects: 224
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BB plus ivermectin
Number of subjects: 224
Study 36097258 — intervention group
Group type: COMPARATOR
Intervention: Topical benzyl benzoate (BB)
Number of subjects: 224
Study 36097258 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin
Number of subjects: 224
Study 33497715 — intervention group
Group type: EXPERIMENTAL
Intervention: JWH-018 (75 μg/kg body weight)
Number of subjects: 24
Study 33497715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36063554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 0
Study 36063554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33988306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicinal products (CBMPs)
Number of subjects: 129
Study 36079749 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g date fruit daily for 12 weeks
Number of subjects: 79
Study 36079749 — intervention group
Group type: COMPARATOR
Intervention: 60 g raisins daily for 12 weeks
Number of subjects: 79
Study 34101010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (Lf)
Number of subjects: 66
Study 34101010 — intervention group
Group type: COMPARATOR
Intervention: Iron hydroxide polymaltose complex (IPC)
Number of subjects: 66
Study 36465461 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualizable steerable sheath (SS)
Number of subjects: 100
Study 36465461 — intervention group
Group type: COMPARATOR
Intervention: Non-visualizable steerable sheath (SS)
Number of subjects: 100
Study 32193070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural competence education programme (4 units, once weekly for 4 weeks, 3 hours each session)
Number of subjects: 97
Study 32193070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97